Skip to main content
SpringerLink
Log in
Book cover

Renal Cancer pp 35–48Cite as

Familial and Hereditary Syndromes in Renal Cell Cancer

  • Chapter
  • First Online:

Abstract

Management of patients with hereditary kidney cancer presents a unique challenge for the urologic surgeon, as patients are often at risk for multiple, bilateral renal surgeries. An understanding of the genetic basis of kidney cancer has led to distinct treatment paradigms in both the surgical management of localized disease and the treatment of advanced disease with systemic therapy. Minimizing the number of interventions and subsequent renal compromise, while maximizing oncologic efficacy, is critical in treating these patients. This chapter reviews the genetics of hereditary kidney cancer with a special emphasis on the translation of genetic insights into contemporary management approaches.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO classification of tumours of the urinary system and male genital organs-part a: renal, penile, and testicular tumours. Eur Urol. 2016;70(1):93–105.

    Article  PubMed  Google Scholar 

  2. Linehan WM. Genetic basis of kidney cancer: role of genomics for the development of disease-based therapeutics. Genome Res. 2012;22(11):2089–100.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.

    Article  PubMed  Google Scholar 

  4. Kletscher BA, Qian J, Bostwick DG, Andrews PE, Zincke H. Prospective analysis of multifocality in renal cell carcinoma: influence of histological pattern, grade, number, size, volume and deoxyribonucleic acid ploidy. J Urol. 1995;153(3 Pt 2):904–6.

    CAS  PubMed  Google Scholar 

  5. Whang M, O'Toole K, Bixon R, Brunetti J, Ikeguchi E, Olsson CA, et al. The incidence of multifocal renal cell carcinoma in patients who are candidates for partial nephrectomy. J Urol. 1995;154(3):968–70; discussion 70–1.

    Article  CAS  PubMed  Google Scholar 

  6. Gudbjartsson T, Jonasdottir TJ, Thoroddsen A, Einarsson GV, Jonsdottir GM, Kristjansson K, et al. A population-based familial aggregation analysis indicates genetic contribution in a majority of renal cell carcinomas. Int J Cancer. 2002;100(4):476–9.

    Article  CAS  PubMed  Google Scholar 

  7. Shuch B, Singer EA, Bratslavsky G. The surgical approach to multifocal renal cancers: hereditary syndromes, ipsilateral multifocality, and bilateral tumors. Urol Clin N Am. 2012;39:133–48.

    Article  Google Scholar 

  8. Ball MW, Singer EA, Srinivasan R. Renal cell carcinoma: molecular characterization and evolving treatment paradigms. Curr Opin Oncol. 2017;29(3):201–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Nielsen SM, Rhodes L, Blanco I, Chung WK, Eng C, Maher ER, et al. Von Hippel-Lindau disease: genetics and role of genetic counseling in a multiple neoplasia syndrome. J Clin Oncol. 2016;34(18):2172–81.

    Article  CAS  PubMed  Google Scholar 

  10. Latif F, Tory K, Gnarra JR, Yao M, Duh FM, Orcutt ML, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. 1993;260(5112):1317–20.

    Article  CAS  PubMed  Google Scholar 

  11. Tory K, Brauch H, Linehan WM, Barba D, Oldfield E, Filling-Katz M, et al. Specific genetic change in tumors associated with von Hippel-Lindau disease. J Natl Cancer Inst. 1989;81:1097–101.

    Article  CAS  PubMed  Google Scholar 

  12. Mandriota SJ, Turner KJ, Davies DR, Murray PG, Morgan NV, Sowter HM, et al. HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell. 2002;1(5):459–68.

    Article  CAS  PubMed  Google Scholar 

  13. Beroud C, Joly D, Gallou C, Staroz F, Orfanelli MT, Junien C. Software and database for the analysis of mutations in the VHL gene. Nucleic Acids Res. 1998;26(1):256–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Nordstrom-O'Brien M, van der Luijt RB, van Rooijen E, van den Ouweland AM, Majoor-Krakauer DF, Lolkema MP, et al. Genetic analysis of von Hippel-Lindau disease. Hum Mutat. 2010;31(5):521–37.

    CAS  PubMed  Google Scholar 

  15. Lonser RR, Glenn GM, Walther M, Chew EY, Libutti SK, Linehan WM, et al. von Hippel-Lindau disease. Lancet. 2003;361(9374):2059–67.

    Article  CAS  PubMed  Google Scholar 

  16. Poston CD, Jaffe GS, Lubensky IA, Solomon D, Zbar B, Linehan WM, et al. Characterization of the renal pathology of a familial form of renal cell carcinoma associated with von Hippel-Lindau disease: clinical and molecular genetic implications. J Urol. 1995;153(1):22–6.

    Article  CAS  PubMed  Google Scholar 

  17. Choyke PL, Filling-Katz MR, Shawker TH, Gorin MB, Travis WD, Chang R, et al. von Hippel-Lindau disease: radiologic screening for visceral manifestations. Radiology. 1990;174(3 Pt 1):815–20.

    Article  CAS  PubMed  Google Scholar 

  18. Duffey BG, Choyke PL, Glenn G, Grubb RL, Venzon D, Linehan WM, et al. The relationship between renal tumor size and metastases in patients with von Hippel-Lindau disease. J Urol. 2004;172(1):63–5.

    Article  PubMed  Google Scholar 

  19. Singer EA, Vourganti S, Lin KY, Gupta GN, Pinto PA, Rastinehad AR, et al. Outcomes of patients with surgically treated bilateral renal masses and a minimum of 10 years of follow-up. J Urol. 2012;188(6):2084–8.

    Article  PubMed  Google Scholar 

  20. Zbar B, Tory K, Merino MJ, Schmidt LS, Glenn GM, Choyke P, et al. Hereditary papillary renal cell carcinoma. J Urol. 1994;151(3):561–6.

    Article  CAS  PubMed  Google Scholar 

  21. Schmidt LS, Duh FM, Chen F, Kishida T, Glenn GM, Choyke P, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet. 1997;16(1):68–73.

    Article  CAS  PubMed  Google Scholar 

  22. Schmidt LS, Junker K, Weirich G, Glenn G, Choyke P, Lubensky I, et al. Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene. Cancer Res. 1998;58(8):1719–22.

    CAS  PubMed  Google Scholar 

  23. Schmidt LS, Junker K, Nakaigawa N, Kinjerski T, Weirich G, Miller M, et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene. 1999;18(14):2343–50.

    Article  CAS  PubMed  Google Scholar 

  24. Lubensky IA, Schmidt LS, Zhuang Z, Weirich G, Pack S, Zambrano N, et al. Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype. Am J Pathol. 1999;155(2):517–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Ornstein DK, Lubensky IA, Venzon D, Zbar B, Linehan WM, Walther MM. Prevalence of microscopic tumors in normal appearing renal parenchyma of patients with hereditary papillary renal cancer. J Urol. 2000;163(2):431–3.

    Article  CAS  PubMed  Google Scholar 

  26. Zbar B, Glenn GM, Lubensky IA, Choyke P, Magnusson G, Bergerheim U, et al. Hereditary papillary renal cell carcinoma: Clinical studies in 10 families. J Urol. 1995;153(3, Supplement 1):907–12.

    CAS  PubMed  Google Scholar 

  27. Schmidt LS, Nickerson ML, Angeloni D, Glenn GM, Walther MM, Albert PS, et al. Early onset Hereditary Papillary Renal Carcinoma: germline missense mutations in the tyrosine kinase domain of the Met proto-oncogene. J Urol. 2004;172(4, Part 1 Of 2):1256–61.

    Article  PubMed  Google Scholar 

  28. Birt AR, Hogg GR, Dube WJ. Hereditary multiple fibrofolliculomas with trichodiscomas and acrochordons. Arch Dermatol. 1977;113(12):1674–7.

    Article  CAS  PubMed  Google Scholar 

  29. Zbar B, Alvord WG, Glenn GM, Turner M, Pavlovich CP, Schmidt LS, et al. Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-Dube syndrome. Cancer Epidemiol Biomarkers Prev. 2002;11(4):393–400.

    PubMed  Google Scholar 

  30. Schmidt LS, Nickerson ML, Warren MB, Glenn GM, Toro JR, Merino MJ, et al. Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dub‚ syndrome. Am J Hum Genet. 2005;76(6):1023–33.

    Google Scholar 

  31. Toro JR, Wei MH, Glenn GM, Weinreich M, Toure O, Vocke CD, et al. BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dube syndrome: a new series of 50 families and a review of published reports. J Med Genet. 2008;45(6):321–31.

    Article  CAS  PubMed  Google Scholar 

  32. Schmidt LS, Linehan WM. Molecular genetics and clinical features of Birt-Hogg-Dube syndrome. Nat Rev Urol. 2015;12(10):558–69.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Pavlovich CP, Walther MM, Eyler RA, Hewitt SM, Zbar B, Linehan WM, et al. Renal tumors in the Birt-Hogg-Dub‚ syndrome. Am J Surg Pathol. 2002;26(12):1542–52.

    Google Scholar 

  34. Leung C, Pan S, Shuch B. Management of renal cell carcinoma in young patients and patients with hereditary syndromes. Curr Opin Urol. 2016;26(5):396–404.

    Article  PubMed  Google Scholar 

  35. Launonen V, Vierimaa O, Kiuru M, Isola J, Roth S, Pukkala E, et al. Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc Natl Acad Sci U S A. 2001;98(6):3387–2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Merino MJ, Torres-Cabala C, Pinto PA, Linehan WM. The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome. Am J Surg Pathol. 2007;31(10):1578–85.

    Article  PubMed  Google Scholar 

  37. Grubb RL III, Franks ME, Toro J, Middelton L, Choyke L, Fowler S, et al. Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer. J Urol. 2007;177(6):2074–80.

    Article  CAS  PubMed  Google Scholar 

  38. Schmidt LS, Linehan WM. Hereditary leiomyomatosis and renal cell carcinoma. Int J Nephrol Renovasc Dis. 2014;7:253–60.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Toro JR, Nickerson ML, Wei MH, Warren MB, Glenn GM, Turner ML, et al. Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am J Hum Genet. 2003;73(1):95–106.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Wei MH, Toure O, Glenn GM, Pithukpakorn M, Neckers L, Stolle C, et al. Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer. J Med Genet. 2006;43(1):18–27.

    Article  CAS  PubMed  Google Scholar 

  41. Tomlinson IP, Alam NA, Rowan AJ, Barclay E, Jaeger EE, Kelsell D, et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet. 2002;30(4):406–10.

    Article  CAS  PubMed  Google Scholar 

  42. Shuch B, Singer EA, Bratslavsky G. The surgical approach to multifocal renal cancers: hereditary syndromes, ipsilateral multifocality, and bilateral tumors. Urol Clin North Am. 2012;39(2):133–48. v.

    Article  PubMed  Google Scholar 

  43. Ricketts CJ, Shuch B, Vocke CD, Metwalli AR, Bratslavsky G, Middelton L, et al. Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer. J Urol. 2012; https://doi.org/10.1016/j.juro.2012.08.030.

  44. Gill AJ, Hes O, Papathomas T, Sedivcova M, Tan PH, Agaimy A, et al. Succinate dehydrogenase (SDH)-deficient renal carcinoma: a morphologically distinct entity: a clinicopathologic series of 36 tumors from 27 patients. Am J Surg Pathol. 2014;38(12):1588–602.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Rai K, Pilarski R, Cebulla CM, Abdel-Rahman MH. Comprehensive review of BAP1 tumor predisposition syndrome with report of two new cases. Clin Genet. 2016;89(3):285–94.

    Article  CAS  PubMed  Google Scholar 

  46. Farley MN, Schmidt LS, Mester JL, Pena-Llopis S, Pavia-Jimenez A, Christie A, et al. Germline BAP1 mutation predisposes to familial clear-cell renal cell carcinoma. Mol Cancer Res. 2013;11:1061.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Popova T, Hebert L, Jacquemin V, Gad S, Caux-Moncoutier V, Dubois-d'Enghien C, et al. Germline BAP1 mutations predispose to renal cell carcinomas. Am J Hum Genet. 2013;92(6):974–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Mir MC, Derweesh I, Porpiglia F, Zargar H, Mottrie A, Autorino R. Partial nephrectomy versus radical nephrectomy for clinical T1b and T2 renal tumors: a systematic review and meta-analysis of comparative studies. Eur Urol. 2016;71(4):606–17.

    Article  PubMed  Google Scholar 

  49. Kauffman EC, Ricketts CJ, Rais-Bahrami S, Yang Y, Merino MJ, Bottaro DP, et al. Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers. Nat Rev Urol. 2014;11(8):465–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Argani P. MiT family translocation renal cell carcinoma. Semin Diagn Pathol. 2015;32(2):103–13.

    Article  PubMed  Google Scholar 

  51. Bertolotto C, Lesueur F, Giuliano S, Strub T, de Lichy M, Bille K, et al. A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature. 2011;480(7375):94–8.

    Article  CAS  PubMed  Google Scholar 

  52. Gorin MA, Ball MW, Pierorazio PM, Argani P, Allaf ME. Partial nephrectomy for the treatment of translocation renal cell carcinoma. Clin Genitourin Cancer. 2015;13(3):e199–201.

    Article  PubMed  Google Scholar 

  53. Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med. 2006;355(13):1345–56.

    Article  CAS  PubMed  Google Scholar 

  54. Bjornsson J, Short MP, Kwiatkowski DJ, Henske EP. Tuberous sclerosis-associated renal cell carcinoma. Clinical, pathological, and genetic features. Am J Pathol. 1996;149(4):1–8.

    Google Scholar 

  55. Kothary N, Soulen MC, Clark TW, Wein AJ, Shlansky-Goldberg RD, Crino PB, et al. Renal angiomyolipoma: long-term results after arterial embolization. J Vasc Interv Radiol. 2005;16(1):45–50.

    Article  PubMed  Google Scholar 

  56. Cristescu M, Abel EJ, Wells S, Ziemlewicz TJ, Hedican SP, Lubner MG, et al. Percutaneous microwave ablation of renal angiomyolipomas. Cardiovasc Intervent Radiol. 2016;39(3):433–40.

    Article  PubMed  Google Scholar 

  57. Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med. 2008;358(2):140–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Cohen AJ, Li FP, Berg S, Marchetto DJ, Tsai S, Jacobs SC, et al. Hereditary renal-cell carcinoma associated with a chromosomal translocation. N Engl J Med. 1979;301:592–5.

    Article  CAS  PubMed  Google Scholar 

  59. van Kessel AG, Wijnhoven H, Bodmer D, Eleveld M, Kiemeney L, Mulders P, et al. Renal cell cancer: chromosome 3 translocations as risk factors. J Natl Cancer Inst. 1999;91(13):1159–60.

    Article  PubMed  Google Scholar 

  60. Rodriguez-Perales S, Melendez B, Gribble SM, Valle L, Carter NP, Santamaria I, et al. Cloning of a new familial t(3;8) translocation associated with conventional renal cell carcinoma reveals a 5 kb microdeletion and no gene involved in the rearrangement. Hum Mol Genet. 2004;13(9):983–90.

    Article  CAS  PubMed  Google Scholar 

  61. Schmidt LS, Li F, Brown RS, Berg S, Chen F, Wei MH, et al. Mechanism of tumorigenesis of renal carcinomas associated with the constitutional chromosome 3;8 translocation. Cancer J Sci Am. 1995;1(3):191–5.

    CAS  PubMed  Google Scholar 

  62. Steinbach F, Novick AC, Zincke H, Miller DP, Williams RD, Lund G, et al. Treatment of renal cell carcinoma in von Hippel-Lindau disease: a multicenter study. J Urol. 1995;153(6):1812–6.

    Article  CAS  PubMed  Google Scholar 

  63. Walther MM, Choyke PL, Glenn G, Lyne JC, Rayford W, Venzon D, et al. Renal cancer in families with hereditary renal cancer: prospective analysis of a tumor size threshold for renal parenchymal sparing surgery. J Urol. 1999;161(5):1475–9.

    Article  CAS  PubMed  Google Scholar 

  64. Pavlovich CP, Grubb RL 3rd, Hurley K, Glenn GM, Toro J, Schmidt LS, et al. Evaluation and management of renal tumors in the Birt-Hogg-Dube syndrome. J Urol. 2005;173(5):1482–6.

    Article  PubMed  Google Scholar 

  65. Al-Saleem T, Wessner LL, Scheithauer BW, Patterson K, Roach ES, Dreyer SJ, et al. Malignant tumors of the kidney, brain, and soft tissues in children and young adults with the tuberous sclerosis complex. Cancer. 1998;83(10):2208–16.

    Article  CAS  PubMed  Google Scholar 

  66. Bjornsson J, Short MP, Kwiatkowski DJ, Henske EP. Tuberous sclerosis-associated renal cell carcinoma. Clinical, pathological, and genetic features. Am J Pathol. 1996;149(4):1201–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  67. Wunderlich H, Schlichter A, Zermann D, Reichelt O, Kosmehl H, Schubert J. Multifocality in renal cell carcinoma: a bilateral event? Urol Int. 1999;63(3):160–3.

    Article  CAS  PubMed  Google Scholar 

  68. Klatte T, Wunderlich H, Patard JJ, Kleid MD, Lam JS, Junker K, et al. Clinicopathological features and prognosis of synchronous bilateral renal cell carcinoma: an international multicentre experience. BJU Int. 2007;100(1):21–5.

    Article  PubMed  Google Scholar 

  69. Calne RY. Treatment of bilateral hypernephromas by nephrectomy, excision of tumour, and autotransplantation. Report of three cases. Lancet. 1973;2(7839):1164–7.

    Article  CAS  PubMed  Google Scholar 

  70. Clark JE. Transplantation for bilateral renal tumors. JAMA. 1970;211(8):1379.

    Article  CAS  PubMed  Google Scholar 

  71. Jochimsen PR, Braunstein PM, Najarian JS. Renal allotransplantation for bilateral renal tumors. JAMA. 1969;210(9):1721–4.

    Article  CAS  PubMed  Google Scholar 

  72. Fadahunsi AT, Sanford T, Linehan WM, Pinto PA, Bratslavsky G. Feasibility and outcomes of partial nephrectomy for resection of at least 20 tumors in a single renal unit. J Urol. 2011;185(1):49–53.

    Article  PubMed  Google Scholar 

  73. Walther MM, Choyke PL, Weiss G, Manolatos C, Long J, Reiter R, et al. Parenchymal sparing surgery in patients with hereditary renal cell carcinoma. J Urol. 1995;153(3 Pt 2):913–6.

    CAS  PubMed  Google Scholar 

  74. Walther MM, Lubensky IA, Venzon D, Zbar B, Linehan WM. Prevalence of microscopic lesions in grossly normal renal parenchyma from patients with von Hippel-Lindau disease, sporadic renal cell carcinoma and no renal disease: clinical implications. J Urol. 1995;154(6):2010–4; discussion 4–5.

    Article  CAS  PubMed  Google Scholar 

  75. Zargar-Shoshtari K, Kim T, Simon R, Lin HY, Yue B, Sharma P, et al. Surveillance following nephron-sparing surgery: an assessment of recurrence patterns and surveillance costs. Urology. 2015;86(2):321–6.

    Article  PubMed  Google Scholar 

  76. Bratslavsky G, Liu JJ, Johnson AD, Sudarshan S, Choyke PL, Linehan WM, et al. Salvage partial nephrectomy for hereditary renal cancer: feasibility and outcomes. J Urol. 2008;179(1):67–70.

    Article  PubMed  Google Scholar 

  77. Johnson A, Sudarshan S, Liu J, Linehan WM, Pinto PA, Bratslavsky G. Feasibility and outcomes of repeat partial nephrectomy. J Urol. 2008;180(1):89–93; discussion.

    Article  PubMed  PubMed Central  Google Scholar 

  78. Liu NW, Khurana K, Sudarshan S, Pinto PA, Linehan WM, Bratslavsky G. Repeat partial nephrectomy on the solitary kidney: surgical, functional and oncological outcomes. J Urol. 2010;183(5):1719–24.

    Article  PubMed  PubMed Central  Google Scholar 

  79. Maurice MJ, Ramirez D, Nelson R, Caputo P, Kara O, Malkoc E, et al. Multiple tumor excisions in ipsilateral kidney increase complications after partial nephrectomy. J Endourol. 2016;30:1200.

    Article  PubMed  Google Scholar 

  80. Minervini A, Serni S, Giubilei G, Lanzi F, Vittori G, Lapini A, et al. Multiple ipsilateral renal tumors: retrospective analysis of surgical and oncological results of tumor enucleation vs radical nephrectomy. Eur J Surg Oncol. 2009;35(5):521–6.

    Article  CAS  PubMed  Google Scholar 

  81. Shuch B, Linehan WM, Bratslavsky G. Repeat partial nephrectomy: surgical, functional and oncological outcomes. Curr Opin Urol. 2011;21(5):368–75.

    Article  PubMed  PubMed Central  Google Scholar 

  82. Carini M, Minervini A, Masieri L, Lapini A, Serni S. Simple enucleation for the treatment of PT1a renal cell carcinoma: our 20-year experience. Eur Urol. 2006;50(6):1263–8; discussion 9–71.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for Cancer Research, NCI, NIH, Urologic Oncology Branch, Bethesda, MD, USA

    Mark Wayne Ball

  2. NIH Clinical Center, Urologic Oncology Branch, Bethesda, MD, USA

    Peter A. Pinto

Authors
  1. Mark Wayne Ball
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter A. Pinto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter A. Pinto .

Editor information

Editors and Affiliations

  1. Professor of Urology, Tufts University School of Medicine, Boston, MA, USA

    John A. Libertino

  2. Associate Professor of Urology, Tufts University School of Medicine, Boston, MA, USA

    Jason R. Gee

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Ball, M.W., Pinto, P.A. (2020). Familial and Hereditary Syndromes in Renal Cell Cancer. In: Libertino, J., Gee, J. (eds) Renal Cancer. Springer, Cham. https://doi.org/10.1007/978-3-030-24378-4_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-24378-4_3

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-24377-7

  • Online ISBN: 978-3-030-24378-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation